林 光博 はやし みつひろ 先生

来歴等

略歴

高知大学 医学部 卒業・熊本大学大学院 卒業、医学博士
熊本大学医学部附属病院（現・熊本大学病院）
熊本市医師会 熊本地域医療センター
熊本大学大学院 生命科学研究部 助教
国立がん研究センター先端医療開発センター
熊本市立熊本市民病院 乳腺内分泌外科 科長

論文

• 【主な論文】

• 1. Developing breast cancer guidelines: keep cherishing our former knowledge as we continue to acquire new. Translational Breast Cancer Research. 2020 Oct;1:23.

  Mitsuhiro Hayashi.

• 2. Phosphoethanolamine Accumulation Protects Cancer Cells under Glutamine Starvation through Downregulation of PCYT2. Cell reports. 2019 Oct 1;29(1):89-103.

  Tsuyoshi Osawa, Teppei Shimamura, Kyoko Saito, Yoko Hasegawa, Naoko Ishii, Miyuki Nishida, Ritsuko Ando, Ayano Kondo, Muyassar Anwar, Rika Tsuchida, et al.

• 3. Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts. Cancer science. 2019 Jul;110(7):2247-2257.

  Masamichi Takahashi, Shunichiro Miki, Kenji Fujimoto, Kohei Fukuoka, Yuko Matsushita, Yoshiko Maida, Mami Yasukawa, Mitsuhiro Hayashi, Raku Shinkyo, Kiyomi Kikuchi, et al.

• 4. Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging. Oncotarget. 2018 Apr 6;9(26):18540-18547.

  Meiko Nishimura, Mitsuhiro Hayashi, Yu Mizutani, Kei Takenaka, Yoshinori Imamura, Naoko Chayahara, Masanori Toyoda, Naomi Kiyota, Toru Mukohara, Hiroaki Aikawa, et al.

• 5. Evaluation of the heterogeneous tissue distribution of erlotinib in lung cancer using matrix-assisted laser desorption ionization mass spectrometry imaging. Scientific reports. 2017 Oct 3;7(1):12622.

  Yukari Tsubata, Mitsuhiro Hayashi, Ryosuke Tanino, Hiroaki Aikawa, Mayu Ohuchi, Kenji Tamura, Yasuhiro Fujiwara, Takeshi Isobe.

• 6. Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer. Medicine. 2015 Dec;94(50):e2290.

  Mitsuhiro Hayashi, Yutaka Yamamoto, Aiko Sueta, Mai Tomiguchi, Mutsuko Yamamoto-Ibusuki, Teru Kawasoe, Hirotaka Iwase.

• 7. Clinical significance of CYLD downregulation in breast cancer. Breast cancer research and treatment. 2014 Feb;143(3):447-457.

  Mitsuhiro Hayashi, Hirofumi Jono, Satoru Shinriki, Takuya Nakamura, Jianying Guo, Aiko Sueta, Mai Tomiguchi, Saori Fujiwara, Mutsuko Yamamoto-Ibusuki, Kei-Ichi Murakami, et al.

• 8. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Annals of surgical oncology. 2012 Sep;19(9):3042-3049.

  Mitsuhiro Hayashi, Yutaka Yamamoto, Mutsuko Ibusuki, Saori Fujiwara, Satoko Yamamoto, Saori Tomita, Masahiro Nakano, Keiichi Murakami, Ken-Ichi Iyama, Hirotaka Iwase.

• 9. Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer.Chinese Clinical Oncology,2020 Jun;9(3) 31-31.

  Mitsuhiro Hayashi, Yutaka Yamamoto, Hirotaka Iwase.

• 10. Histone deacetylase inhibition enhances the therapeutic effects of methotrexate on primary central nervous system lymphoma.Neuro-Oncology Advances.2020 Jan 1;2(1)

  Kenji Fujimoto, Naoki Shinojima, Mitsuhiro Hayashi, Tomoyuki Nakano, Koichi Ichimura, Akitake Mukasa.

• 11. Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development. Drug Metabolism and Pharmacokinetics.2019 Aug;34(4) 209-216.

  Masanobu Nishidate, Mitsuhiro Hayashi, Hiroaki Aikawa, Kouji Tanaka, Naoyuki Nakada, Shin-Ichi Miura, Shoraku Ryu, Tatsuya Higashi, Yoshinori Ikarashi, Yasuhiro Fujiwara.

• 12. Tissue 2-Hydroxyglutarate and Preoperative Seizures in Patients With Diffuse Gliomas. Neurology.2021 Nov 23;97(21) e2114-e2123.

  Makoto Ohno, Yoshiharu Hayashi, Hiroaki Aikawa, Mitsuhiro Hayashi, Yasuji Miyakita, Masamichi Takahashi, Yuko Matsushita, Akihiko Yoshida, Kaishi Satomi, Koichi Ichimura et al.

• 13. Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study. British Journal of Pharmacology. 2018 Jan;175(1) 29-37.

  Shoraku Ryu, Mitsuhiro Hayashi, Hiroaki Aikawa, Isamu Okamoto, Yasuhiro Fujiwara.

• 14. Eribulin is a novel TERT-targeting inhibitor that penetrates into intracerebrally grown glioblastomas and suppresses their growth in mice.CANCER RESEARCH 77. 2017 Jul.

  Takahashi Masamichi, Miki Shunichiro, Matsushita Yuko, Fukuoka Kohei, Maida Yoshiko, Yasukawa Mami, Hayashi Mitsuhiro, Mukasa Akitake, Nishikawa Ryo, Tamura Kenji et al.

• 15. Docetaxel and cyclophosphamide chemotherapy induced radiation recall phenomenon in a postoperative breast cancer patient: a case report. International Cancer Conference Journal.2016 Oct;5(4) 202-205.

  Mai Tomiguchi, Yutaka Yamamoto, Mitsuhiro Hayashi, Mutsuko Yamamoto-Ibusuki, Keiichi Murakami, Hirotaka Iwase.

• 16. Successful ethinylestradiol therapy for a metastatic breast cancer patient with heavily pre-treated with endocrine therapies.International Cancer Conference Journal. 2016 Jul;5(3) 126-130.

  Aiko Sueta, Mitsuhiro Hayashi, Yoshiyuki Fukugawa, Hirokazu Shimizu, Mutsuko Yamamoto-Ibusuki, Yutaka Yamamoto, Hirotaka Iwase.

• 17. Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging.Scientific Reports 6.2016 Mar.30;23749-23749.

  Hiroaki Aikawa, Mitsuhiro Hayashi, Shoraku Ryu, Makiko Yamashita, Naoto Ohtsuka, Masanobu Nishidate, Yasuhiro Fujiwara.

• 18. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes? Surgery.2014 May;155(5) 927-35.

  Aiko Sueta, Yutaka Yamamoto, Mitsuhiro Hayashi, Satoko Yamamoto, Toko Inao, Mutsuko Ibusuki, Keiichi Murakami, Hirotaka Iwase.

• 19. A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character. SpringerPlus.2013 Dec;2(1) 272-272.

  Mitsuhiro Hayashi, Yutaka Yamamoto, Noboru Takata, Hirotaka Iwase.

• 20. Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer. International journal of clinical oncology.2011 Dec;16(6) 694-700.

  Mitsuhiro Hayashi, Yasuhiro Okumura, Tomofumi Osako, Yasuo Toyozumi, Nobuyuki Arima, Hirotaka Iwase, Reiki Nishimura.

• 21. Shift in cytotoxic target from estrogen receptor-positive to estrogen receptor-negative breast cancer cells by trastuzumab in combination with taxane-based chemotherapy. Oncology letters.2011 Mar;2(2) 303-308.

  Mitsuhiro Hayashi, Kazuharu Kai, Yasuhiro Okumura, Tomofumi Osako, Nobuyuki Arima, Hirotaka Iwase, Reiki Nishimura.

もっと見る

その他

• 【主な公的研究】

• 1. 乳癌PDXモデルを活用した循環腫瘍DNAに関するリバーストランスレーショナル研究.科学研究費助成事業 2018年-

• 2. 医薬品開発における質量分析イメージング技術の標準化に向けた取り組み.AMED 医薬品等規制調和・評価研究事業 2018年-

• 3. 癌の生命予後規定因子CYLDの分子診断を突破口とした従来にない分子標的治療の確立.科学研究費助成事業 2018年-

• 4. Deciphering and Targeting the Link between Obesity and Cancer.New York Academy of Sciences and AMED Interstellar Initiative 2017年-

• 5. がん医療推進のための日本人がん患者由来PDXライブラリー整備事業.AMED 医療研究開発革新基盤創成事業 2017年-

• 6. 分子イメージングによる治療抵抗性腫瘍の薬物動態とがん微小環境研究.AMED 次世代がん医療創生研究事業 2016年-

• 7. 腫瘍生物学的因子と患者の肥満や糖・脂質代謝異常を背景として新規乳癌亜型分類の構築.科学研究費助成事業 若手研究B 2015年-

• 8. 患者乳癌組織移植モデルと質量分析イメージングによる空間薬物動態解析を用いた新視点からの創薬支援研究開発 .AMED 革新的がん医療創生研究事業 2015年-